NASDAQ:BPMCBlueprint Medicines Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Blueprint Medicines Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $71.17 +1.66 (+2.39 %) (As of 06/5/2020 04:00 PM ET) Add Compare Share Today's Range$68.08Now: $71.17▼$72.6550-Day Range$57.15MA: $65.00▼$74.5352-Week Range$43.29Now: $71.17▼$102.98Volume422,753 shsAverage Volume611,643 shsMarket Capitalization$3.86 billionP/E RatioN/ADividend YieldN/ABeta1.09 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which completed Phase I clinical trials that targets PDGFRA Exon 18 mutant GIST and KIT-driven GIST; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma. It is also developing BLU-667, an orally available and potent inhibitor that targets RET, a receptor tyrosine kinase that is abnormally activated by mutations or translocations; and RET resistant mutants that would arise from treatment with first generation therapies. In addition, the company is developing BLU-782, an inhibitor targeting the kinase ALK2 for the treatment of fibrodysplasia ossificans progressiva, a rare genetic disease caused by mutations in the ALK2 gene, ACVR1. The company has collaboration and license agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to discover, develop, and commercialize small molecule therapeutics targeting kinases. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts.Read More Beat the Market (BTM) Rank™ 4.5 Analyst's Opinion Consensus RatingBlueprint Medicines has received a consensus rating of Buy. The company's average rating score is 2.92, and is based on 10 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $91.42, Blueprint Medicines has a potential upside of 28.4% from its current price of $71.17.Amount of Analyst CoverageBlueprint Medicines has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Community Rank Outperform VotesBlueprint Medicines has received 435 “outperform” votes. (Add your “outperform” vote.)Underperform VotesBlueprint Medicines has received 299 “underperform” votes. (Add your “underperform” vote.)Community SentimentBlueprint Medicines has received 59.26% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Blueprint Medicines and other stocks. Vote “Outperform” if you believe BPMC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BPMC will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldBlueprint Medicines does not currently pay a dividend.Dividend GrowthBlueprint Medicines does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Blueprint Medicines insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,399,123.00 in company stock.Percentage Held by InsidersOnly 4.02% of the stock of Blueprint Medicines is held by insiders.Percentage Held by Institutions97.95% of the stock of Blueprint Medicines is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Blueprint Medicines are expected to grow in the coming year, from ($8.42) to ($6.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Blueprint Medicines is -9.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Blueprint Medicines is -9.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBlueprint Medicines has a P/B Ratio of 7.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.82 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BPMC Previous Symbol CUSIPN/A CIK1597264 Webwww.blueprintmedicines.com Phone617-374-7580Debt Debt-to-Equity Ratio0.13 Current Ratio7.17 Quick Ratio7.14Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$66.51 million Price / Sales57.99 Cash FlowN/A Price / Cash FlowN/A Book Value$9.44 per share Price / Book7.54Profitability EPS (Most Recent Fiscal Year)($7.27) Net Income$-347,690,000.00 Net Margins-515.98% Return on Equity-65.81% Return on Assets-46.90%Miscellaneous Employees217 Outstanding Shares54,190,000Market Cap$3.86 billion Next Earnings Date8/6/2020 (Estimated) OptionableOptionable NASDAQ:BPMC Rates by TradingView Receive BPMC News and Ratings via Email Sign-up to receive the latest news and ratings for BPMC and its competitors with MarketBeat's FREE daily newsletter. Blueprint Medicines (NASDAQ:BPMC) Frequently Asked Questions How has Blueprint Medicines' stock been impacted by COVID-19 (Coronavirus)? Blueprint Medicines' stock was trading at $52.42 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, BPMC shares have increased by 35.8% and is now trading at $71.17. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Blueprint Medicines? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Blueprint Medicines in the last year. There are currently 2 hold ratings, 10 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Blueprint Medicines. When is Blueprint Medicines' next earnings date? Blueprint Medicines is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Blueprint Medicines. How were Blueprint Medicines' earnings last quarter? Blueprint Medicines Corp (NASDAQ:BPMC) announced its earnings results on Wednesday, May, 6th. The biotechnology company reported ($2.11) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($2.08) by $0.03. The biotechnology company had revenue of $6.20 million for the quarter, compared to analyst estimates of $5.57 million. Blueprint Medicines had a negative net margin of 515.98% and a negative return on equity of 65.81%. The firm's revenue for the quarter was up 749.3% on a year-over-year basis. During the same quarter in the previous year, the business posted ($1.98) earnings per share. View Blueprint Medicines' earnings history. What price target have analysts set for BPMC? 13 brokers have issued 1-year target prices for Blueprint Medicines' stock. Their forecasts range from $59.00 to $122.00. On average, they anticipate Blueprint Medicines' share price to reach $91.42 in the next twelve months. This suggests a possible upside of 28.4% from the stock's current price. View analysts' price targets for Blueprint Medicines. Has Blueprint Medicines been receiving favorable news coverage? Media headlines about BPMC stock have trended somewhat negative this week, InfoTrie Sentiment reports. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Blueprint Medicines earned a media sentiment score of -1.0 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutBlueprint Medicines. Who are some of Blueprint Medicines' key competitors? Some companies that are related to Blueprint Medicines include Merck KGaA (MKGAF), Teva Pharmaceutical Industries (TEVA), GRIFOLS S A/S (GRFS), Beigene (BGNE), GALAPAGOS NV/S (GLPG), Catalent (CTLT), Sarepta Therapeutics (SRPT), Ono Pharmaceutical (OPHLF), Mylan (MYL), Horizon Therapeutics (HZNP), Elanco Animal Health (ELAN), Dr.Reddy's Laboratories (RDY), Ionis Pharmaceuticals (IONS), Perrigo (PRGO) and ACADIA Pharmaceuticals (ACAD). View all competitors. What other stocks do shareholders of Blueprint Medicines own? Based on aggregate information from My MarketBeat watchlists, some companies that other Blueprint Medicines investors own include Advanced Micro Devices (AMD), Micron Technology (MU), AbbVie (ABBV), Crispr Therapeutics (CRSP), Amarin (AMRN), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), Nektar Therapeutics (NKTR), Alibaba Group (BABA) and Gilead Sciences (GILD). Who are Blueprint Medicines' key executives? Blueprint Medicines' management team includes the following people: Mr. Jeffrey W. Albers, CEO, Pres & Director (Age 48)Mr. Alexis A. Borisy, Co-Founder & Director (Age 47)Mr. Michael Landsittel, Chief Financial Officer (Age 47)Ms. Kathryn Haviland, Chief Operating Officer (Age 43)Dr. Christopher K. Murray, Sr. VP of Technical Operations (Age 56) When did Blueprint Medicines IPO? (BPMC) raised $115 million in an initial public offering on Thursday, April 30th 2015. The company issued 7,200,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Cowen and Company served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. What is Blueprint Medicines' stock symbol? Blueprint Medicines trades on the NASDAQ under the ticker symbol "BPMC." Who are Blueprint Medicines' major shareholders? Blueprint Medicines' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.68%), State Street Corp (3.62%), Viking Global Investors LP (2.95%), Casdin Capital LLC (2.86%), Wellington Management Group LLP (2.77%) and Invesco Ltd. (2.31%). Company insiders that own Blueprint Medicines stock include Alexis Borisy, Anthony L Boral, Ariel Hurley, Charles A Rowland Jr, George Demetri, Jeffrey W Albers, Kate Haviland, Lonnel Coats, Marion Dorsch and Nicholas Lydon. View institutional ownership trends for Blueprint Medicines. Which institutional investors are selling Blueprint Medicines stock? BPMC stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Invesco Ltd., Lord Abbett & CO. LLC, TimesSquare Capital Management LLC, Eagle Asset Management Inc., Carillon Tower Advisers Inc., Rafferty Asset Management LLC, and Alliancebernstein L.P.. Company insiders that have sold Blueprint Medicines company stock in the last year include Alexis Borisy, Anthony L Boral, Ariel Hurley, Charles A Rowland Jr, George Demetri, Jeffrey W Albers, Kate Haviland, Lonnel Coats, Marion Dorsch, and Nicholas Lydon. View insider buying and selling activity for Blueprint Medicines. Which institutional investors are buying Blueprint Medicines stock? BPMC stock was acquired by a variety of institutional investors in the last quarter, including Casdin Capital LLC, BlackRock Inc., Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Rock Springs Capital Management LP, Eaton Vance Management, Viking Global Investors LP, and First Manhattan Co.. View insider buying and selling activity for Blueprint Medicines. How do I buy shares of Blueprint Medicines? Shares of BPMC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Blueprint Medicines' stock price today? One share of BPMC stock can currently be purchased for approximately $71.17. How big of a company is Blueprint Medicines? Blueprint Medicines has a market capitalization of $3.86 billion and generates $66.51 million in revenue each year. The biotechnology company earns $-347,690,000.00 in net income (profit) each year or ($7.27) on an earnings per share basis. Blueprint Medicines employs 217 workers across the globe. What is Blueprint Medicines' official website? The official website for Blueprint Medicines is www.blueprintmedicines.com. How can I contact Blueprint Medicines? Blueprint Medicines' mailing address is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-374-7580 or via email at [email protected] This page was last updated on 6/7/2020 by MarketBeat.com Staff
